Jamie L. Redes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jamie L. Redes has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Albert C. Sek
Inflammation Immunobiology Section, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland, USA
1 shared publication Chandra C. Ghosh
Center for Vascular Biology Research, Department of Emergency Medicine, Beth Israel Deaconess Medical Center , Boston, MA 02215
1 shared publicationErik P. Karmele
Immunopathogenesis Section, Laboratory of Parasitic Diseases National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda MD USA
1 shared publicationEunice C. Chan
Lung and Vascular Inflammation Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases/National Institutes of Health , Bethesda, MD 20892
1 shared publicationHelene F. Rosenberg
Inflammation Immunobiology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases/National Institutes of Health , Bethesda, MD 20892
1 shared publication- Joshua C. Sciurba
Affiliation Laboratory of Parasitic Diseases, NIAID, National Institutes of Health; Bethesda, Maryland, United States of America
1 shared publication
Latest Publications
- Open Access
- 1 August 2019
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 3 (8) , 368-377
Aspergillus fumigatus–Secreted Alkaline Protease 1 Mediates Airways Hyperresponsiveness in Severe Asthma
The hallmark features of allergic asthma are type 2 (eosinophilic) inflammation and airways hyperresponsiveness (AHR). Although these features often comanifest in mouse lungs in vivo, we demonstrate in this study that the serine protease Alp1 from the ubiquitous mold and allergen, Aspergillus fumigatus, can induce AHR in mice unable to generate eosinophilic inflammation. Strikingly, Alp1 induced AHR in mice devoid of protease-activated receptor 2/F2 trypsin-like receptor 1 (PAR2/F2RL1), a receptor expressed in lung epithelium that is critical for allergic responses to protease-containing allergens. Instead, using precision-cut lung slices and human airway smooth muscle cells, we demonstrate that Alp1 directly increased contractile force. Taken together, these findings suggest that Alp1 induces bronchoconstriction through mechanisms that are largely independent of allergic inflammation and point to a new target for direct intervention of fungal-associated asthma.
- 1 August 2019
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 3 (8) , 368-377
Open AccessAspergillus fumigatus–Secreted Alkaline Protease 1 Mediates Airways Hyperresponsiveness in Severe Asthma
The hallmark features of allergic asthma are type 2 (eosinophilic) inflammation and airways hyperresponsiveness (AHR). Although these features often comanifest in mouse lungs in vivo, we demonstrate in this study that the serine protease Alp1 from the ubiquitous mold and allergen, Aspergillus fumigatus, can induce AHR in mice unable to generate eosinophilic inflammation. Strikingly, Alp1 induced AHR in mice devoid of protease-activated receptor 2/F2 trypsin-like receptor 1 (PAR2/F2RL1), a receptor expressed in lung epithelium that is critical for allergic responses to protease-containing allergens. Instead, using precision-cut lung slices and human airway smooth muscle cells, we demonstrate that Alp1 directly increased contractile force. Taken together, these findings suggest that Alp1 induces bronchoconstriction through mechanisms that are largely independent of allergic inflammation and point to a new target for direct intervention of fungal-associated asthma.
- Open Access
- 7 December 2018
- Published by Wiley in The Journal of Pathology
- Vol. 248 (1) , 16-29
Fibroblast‐specific integrin‐alpha V differentially regulates type 17 and type 2 driven inflammation and fibrosis
Fibroproliferative diseases affect a significant proportion of the world's population. Despite this, core mechanisms driving organ fibrosis of diverse etiologies remain ill defined. Recent studies suggest that integrin‐alpha V serves as a master driver of fibrosis in multiple organs. Although diverse mechanisms contribute to the progression of fibrosis, TGF‐β and IL‐13 have emerged as central mediators of fibrosis during type 1/type 17, and type 2 polarized inflammatory responses, respectively. To investigate if integrin‐alpha V interactions or signaling is critical to the development of type 2 fibrosis, we analyzed fibroblast‐specific integrin‐alpha V knockout mice in three type 2‐driven inflammatory disease models. While we confirmed a role for integrin‐alpha V in type 17‐associated fibrosis, integrin‐alpha V was not critical to the development of type 2‐driven fibrosis. Additionally, our studies support a novel mechanism through which fibroblasts, via integrin‐alpha V expression, are capable of regulating immune polarization. We show that when integrin‐alpha V is deleted on fibroblasts, initiation of type 17 inflammation is inhibited leading to a deregulation of type 2 inflammation. This mechanism is most evident in a model of severe asthma, which is characterized by a mixed type 2/type 17 inflammatory response. Together, these findings suggest dual targeting of integrin‐alpha V and type 2 pathways may be needed to ameliorate fibrosis and prevent rebound of opposing pro‐fibrotic and inflammatory mechanisms. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 7 December 2018
- Published by Wiley in The Journal of Pathology
- Vol. 248 (1) , 16-29
Open AccessFibroblast‐specific integrin‐alpha V differentially regulates type 17 and type 2 driven inflammation and fibrosis
Fibroproliferative diseases affect a significant proportion of the world's population. Despite this, core mechanisms driving organ fibrosis of diverse etiologies remain ill defined. Recent studies suggest that integrin‐alpha V serves as a master driver of fibrosis in multiple organs. Although diverse mechanisms contribute to the progression of fibrosis, TGF‐β and IL‐13 have emerged as central mediators of fibrosis during type 1/type 17, and type 2 polarized inflammatory responses, respectively. To investigate if integrin‐alpha V interactions or signaling is critical to the development of type 2 fibrosis, we analyzed fibroblast‐specific integrin‐alpha V knockout mice in three type 2‐driven inflammatory disease models. While we confirmed a role for integrin‐alpha V in type 17‐associated fibrosis, integrin‐alpha V was not critical to the development of type 2‐driven fibrosis. Additionally, our studies support a novel mechanism through which fibroblasts, via integrin‐alpha V expression, are capable of regulating immune polarization. We show that when integrin‐alpha V is deleted on fibroblasts, initiation of type 17 inflammation is inhibited leading to a deregulation of type 2 inflammation. This mechanism is most evident in a model of severe asthma, which is characterized by a mixed type 2/type 17 inflammatory response. Together, these findings suggest dual targeting of integrin‐alpha V and type 2 pathways may be needed to ameliorate fibrosis and prevent rebound of opposing pro‐fibrotic and inflammatory mechanisms. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.